Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_assertion evidence source_evidence_literature NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_assertion SIO_000772 15781610 NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_assertion wasDerivedFrom befree-20140225 NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_assertion wasGeneratedBy ECO_0000203 NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.
- befree-20140225 importedOn "2014-02-25" NP644855.RAOQ18Jz_ayzCbs0KGZTEGqL2Iml7hjNYnDMnCRr6Tnlg130_provenance.